CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

249 papers

Active filtersClassification:Core

Showing 133-144 of total 249 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

The Right Key, the Wrong Lock: TIGIT Checkpoint Blockade and the Road to Precision Immunotherapy.

Smail SW; Hamza HT; Ali MA; Yashooa RK; Nooh WA; Bapir AA; Rahman DB; Rahman MO; Haseeb HA; Maaruf NB; Majeed SO; Ezzat I; Janson C

2026PubMedDirectly related

Extracting adverse event nature, severity, timelines and resulting interventions from clinical notes of patients receiving CAR-T cell therapy using large language models.

Guillot J; Miao B; Suresh A; Sushil M; Williams CYK; Vashisht R; Oskotsky TT; Sirota M; Butte AJ

Jan 1, 2026PLOS digital health

2026PubMedDirectly related

Navigating CAR-T translation in Australia: lessons from an academic program.

Tan RPA; Walsh R; McCowage G; O'Neill GM; Gowrishankar K

Jan 1, 2026Frontiers in medicine

2026PubMedDirectly related

CAR-T cells and CAR-Treg cells for treatment of inflammatory bowel diseases.

Neurath MF

Jan 1, 2026EULAR rheumatology open

2026PubMedDirectly related

IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting.

Gehrcken L; Ott J; Van den Eynde A; Lau HW; Liu D; Hermans C; Verhezen T; Peeters S; Faghel C; Joye P; Roex G; Campillo-Davo D; Lion E; Elvas F; Koljenovic S; De Waele J; Hartman V; Roeyen G; Prenen H; Lardon F; Deben C; Smits E; Van Audenaerde J

Jan 1, 2026Molecular therapy. Oncology

2026PubMedDirectly related

Suspension-Adapted HEK293FT Cells Enable High-Density Transfection for Efficient Lentiviral Vector Production in CAR-T Therapy.

Shevtsov A; Kydyrbayeva A; Nigmatulla G; Keyer V; Kulatay T; Zauatbayeva G; Ingirbay B; Zhumabekova M; Zharlyganova D; Shustov AV

Jan 1, 2026Bioengineering (Basel, Switzerland)

2026PubMedDirectly related

Armoring CAR-T Cells Against Exhaustion: Engineering Strategies for Glioblastoma.

Anvarian A; Nazari FSM; Karimi Jashni A

Jan 1, 2026Journal of immunotherapy (Hagerstown, Md. : 1997)

2026PubMedDirectly related

Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.

Krawczyk M; Fidyt K; Fernandez-Fuentes N; Winiarski T; Pepek M; Bousquets-Muñoz P; Puente XS; Gutiérrez-Fernández A; Davis J; Owczarek D; Graczyk-Jarzynka A; Sanz-Galarreta P; Menendez P; Szumera-Ciećkiewicz A; Benard E; Wälchli S; Thomas-Tikhonenko A; Pérez-García VM; Galán-Gómez V; Escudero López A; Delgado EI; Minguillón J; Pérez-Martínez A; Winiarska M

Jan 1, 2026Leukemia

2026PubMedDirectly related

Single-Chain Variable Fragment Fusion Proteins for Targeted Delivery and Therapy.

Yang L; Yin Y; Liu X; Guo B

Jan 1, 2026Pharmaceuticals (Basel, Switzerland)

2026PubMedDirectly related

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

Kersten MJ; Kuipers MT; Mutsaers PGNJ; Willems E; Saevels K; Dreyling M; Jacobson C; Bishop MR; Zandvliet M; Milatos S; Lobetti-Bodoni C; Blum S; Van Hoorde K; Desai J; Acciarri L; Pont MJ; van Muyden A; Fasan O; Vermaat JSP; Anguille S

Jan 1, 2026The Lancet. Haematology

2026PubMedDirectly related

InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL.

Galli E; Mannina D; Corrente A; De Philippis C; Pansini I; Viscovo M; Hohaus S; Chiusolo P; Sorà F; Bramanti S; Sica S

Jan 1, 2026European journal of haematology

2026PubMedDirectly related

B-cell depletion therapy in systemic lupus erythematosus: emerging strategies and challenges.

Mok TC; Mok CC

Jan 1, 2026Expert opinion on biological therapy